Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| STERIS plcSTE · Entity 3228 | Director | June 02, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
STERIS plc
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 38,964 |
Ending reported balance
After 2026-06-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-02 · Exercise / conversion · Acquired 3,781 · Balance 40,445 Row 2 · 2026-06-02 · Sale · Disposed 1,481 · Balance 38,964 F1: Price reflects a weighted average sale price for multiple transactions ranging from $209.50 to $209.53 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.40 · Expires 2026-08-10 | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-02 · Exercise / conversion · Disposed 3,781 · Balance 0 F4: This option to purchase 3,781 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 3,781 ordinary shares for $71.40 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes Below | 27,242 |
Reported balance
Holding disclosure · report date 2026-06-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 27,242 F2: Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC (the "General Partner") is in turn the general partner of Breeden Partners L.P. (the "Fund"). F3: Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Mr. Breeden disclaims beneficial ownership over 1,358 of these shares held by Breeden Partnership LLP. |
Filing footnotes · ownership attribution and instrument terms
F1: Price reflects a weighted average sale price for multiple transactions ranging from $209.50 to $209.53 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2: Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC (the "General Partner") is in turn the general partner of Breeden Partners L.P. (the "Fund").
F3: Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Mr. Breeden disclaims beneficial ownership over 1,358 of these shares held by Breeden Partnership LLP.
F4: This option to purchase 3,781 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 3,781 ordinary shares for $71.40 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STERIS plc
Report date March 28, 2019 · Filed March 28, 2019
Section 16 reporting ended · disclosed 2019-03-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, 10 pence par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 1
1 source rowRow 1 · 2019-03-28 · Disposition to issuer · Disposed 28,548 · Balance 0 F1: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"), cancelled pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS"), in an amount equal to the number of the reporting person's cancelled Old STERIS shares. The reporting person's STERIS shares will be subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS. |
| Ordinary Shares, 10 pence par valueSEC Table I · non-derivative | IndirectSee Footnote Below. | 0 |
Reported balance
After 2019-03-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-03-28 · Disposition to issuer · Disposed 72,242 · Balance 0 F1: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"), cancelled pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS"), in an amount equal to the number of the reporting person's cancelled Old STERIS shares. The reporting person's STERIS shares will be subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS. F2: Richard C. Breeden is the managing member of Breeden Capital Partners LLC, managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC is in turn the general partner of Breeden Partners L.P. (the "Fund"). F3: Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.34 · Expires 2020-08-04 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-28 · Disposition to issuer · Disposed 3,133 · Balance 0 F4: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,133 ordinary shares of STERIS for $32.34 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.61 · Expires 2021-08-03 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-28 · Disposition to issuer · Disposed 3,121 · Balance 0 F5: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,121 ordinary shares of STERIS for $31.61 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.36 · Expires 2022-08-03 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-03-28 · Disposition to issuer · Disposed 3,218 · Balance 0 F6: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,218 ordinary shares of STERIS for $32.36 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.92 · Expires 2023-08-08 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-28 · Disposition to issuer · Disposed 4,657 · Balance 0 F7: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,657 ordinary shares of STERIS for $43.92 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.53 · Expires 2024-08-06 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-03-28 · Disposition to issuer · Disposed 4,584 · Balance 0 F8: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,584 ordinary shares of STERIS for $51.53 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.05 · Expires 2025-08-31 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-03-28 · Disposition to issuer · Disposed 4,110 · Balance 0 F9: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,110 ordinary shares of STERIS for $64.05 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.40 · Expires 2026-08-10 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-03-28 · Disposition to issuer · Disposed 3,781 · Balance 0 F10: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,781 ordinary shares of STERIS for $71.40 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.23 · Expires 2027-08-09 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-03-28 · Disposition to issuer · Disposed 4,058 · Balance 0 F11: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,058 ordinary shares of STERIS for $86.23 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.74 · Expires 2028-08-09 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-03-28 · Disposition to issuer · Disposed 3,495 · Balance 0 F12: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,495 ordinary shares of STERIS for $114.74 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Career Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-03-28 · Disposition to issuer · Disposed 12,716 · Balance 0 F13: These career restricted stock units were assumed by STERIS pursuant to the Scheme and converted to career restricted stock units of STERIS representing the right to receive 12,716 STERIS ordinary shares. These career restricted stock units are fully vested and will be settled in STERIS ordinary shares six months after the cessation of the reporting person's board service, subject to the terms and conditions of the award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"), cancelled pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS"), in an amount equal to the number of the reporting person's cancelled Old STERIS shares. The reporting person's STERIS shares will be subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS.
F2: Richard C. Breeden is the managing member of Breeden Capital Partners LLC, managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC is in turn the general partner of Breeden Partners L.P. (the "Fund").
F3: Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares.
F4: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,133 ordinary shares of STERIS for $32.34 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F5: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,121 ordinary shares of STERIS for $31.61 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F6: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,218 ordinary shares of STERIS for $32.36 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F7: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,657 ordinary shares of STERIS for $43.92 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F8: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,584 ordinary shares of STERIS for $51.53 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F9: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,110 ordinary shares of STERIS for $64.05 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F10: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,781 ordinary shares of STERIS for $71.40 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F11: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,058 ordinary shares of STERIS for $86.23 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F12: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,495 ordinary shares of STERIS for $114.74 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F13: These career restricted stock units were assumed by STERIS pursuant to the Scheme and converted to career restricted stock units of STERIS representing the right to receive 12,716 STERIS ordinary shares. These career restricted stock units are fully vested and will be settled in STERIS ordinary shares six months after the cessation of the reporting person's board service, subject to the terms and conditions of the award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantDirector Stock Option (right to buy) · Derivative | 3,495 | Not disclosed Strike: $114.74 | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · derivative · entry 11 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,495 Underlying: Ordinary Shares · 3,495 shares Expires 2028-08-09 F12 · price: This option to purchase 3,495 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,495 Old STERIS ordinary shares for $114.74 per share, subject to the same terms and conditions as the original Old STERIS stock option. F12 · derivative.exercise_date: This option to purchase 3,495 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,495 Old STERIS ordinary shares for $114.74 per share, subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantDirector Stock Option (right to buy) · Derivative | 4,058 | Not disclosed Strike: $86.23 | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · derivative · entry 10 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,058 Underlying: Ordinary Shares · 4,058 shares Expires 2027-08-09 F11 · price: This option to purchase 4,058 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 4,058 Old STERIS ordinary shares for $86.23 per share, subject to the same terms and conditions as the original Old STERIS stock option. F11 · derivative.exercise_date: This option to purchase 4,058 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 4,058 Old STERIS ordinary shares for $86.23 per share, subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantDirector Stock Option (right to buy) · Derivative | 3,781 | Not disclosed Strike: $71.40 | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · derivative · entry 9 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,781 Underlying: Ordinary Shares · 3,781 shares Expires 2026-08-10 F10 · price: This option to purchase 3,781 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,781 Old STERIS ordinary shares for $71.40 per share, subject to the same terms and conditions as the original Old STERIS stock option. F10 · derivative.exercise_date: This option to purchase 3,781 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,781 Old STERIS ordinary shares for $71.40 per share, subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantDirector Stock Option (right to buy) · Derivative | 4,110 | Not disclosed Strike: $64.05 | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · derivative · entry 8 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,110 Underlying: Ordinary Shares · 4,110 shares Expires 2025-08-31 F9 · price: This option to purchase 4,110 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 4,110 Old STERIS ordinary shares for $64.05 per share, subject to the same terms and conditions as the original Old STERIS stock option. F9 · derivative.exercise_date: This option to purchase 4,110 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 4,110 Old STERIS ordinary shares for $64.05 per share, subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantDirector Stock Option (right to buy) · Derivative | 4,584 | Not disclosed Strike: $51.53 | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · derivative · entry 7 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 Underlying: Ordinary Shares · 4,584 shares Expires 2024-08-06 F8 · price: This option to purchase 4,584 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 4,584 Old STERIS ordinary shares for $51.53 per share, subject to the same terms and conditions as the original Old STERIS stock option. F8 · derivative.exercise_date: This option to purchase 4,584 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 4,584 Old STERIS ordinary shares for $51.53 per share, subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantDirector Stock Option (right to buy) · Derivative | 4,657 | Not disclosed Strike: $43.92 | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · derivative · entry 6 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,657 Underlying: Ordinary Shares · 4,657 shares Expires 2023-08-08 F7 · price: This option to purchase 4,657 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 4,657 Old STERIS ordinary shares for $43.92 per share, subject to the same terms and conditions as the original Old STERIS stock option. F7 · derivative.exercise_date: This option to purchase 4,657 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 4,657 Old STERIS ordinary shares for $43.92 per share, subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantDirector Stock Option (right to buy) · Derivative | 3,218 | Not disclosed Strike: $32.36 | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · derivative · entry 5 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,218 Underlying: Ordinary Shares · 3,218 shares Expires 2022-08-03 F6 · price: This option to purchase 3,218 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,218 Old STERIS ordinary shares for $32.36 per share, subject to the same terms and conditions as the original Old STERIS stock option. F6 · derivative.exercise_date: This option to purchase 3,218 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,218 Old STERIS ordinary shares for $32.36 per share, subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantDirector Stock Option (right to buy) · Derivative | 3,121 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · derivative · entry 4 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,121 Underlying: Ordinary Shares · 3,121 shares Expires 2021-08-03 F5 · price: This option to purchase 3,121 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,121 Old STERIS ordinary shares for $31.61 per share, subject to the same terms and conditions as the original Old STERIS stock option. F5 · derivative.exercise_date: This option to purchase 3,121 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,121 Old STERIS ordinary shares for $31.61 per share, subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantDirector Stock Option (right to buy) · Derivative | 3,133 | Not disclosed Strike: $32.34 | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · derivative · entry 3 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,133 Underlying: Ordinary Shares · 3,133 shares Expires 2020-08-04 F4 · price: This option to purchase 3,133 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,133 Old STERIS ordinary shares for $32.34 per share, subject to the same terms and conditions as the original Old STERIS stock option. F4 · derivative.exercise_date: This option to purchase 3,133 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,133 Old STERIS ordinary shares for $32.34 per share, subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantOrdinary Shares | 72,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · nonDerivative · entry 2 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Below. Disclosed balance after: 72,242 F1 · price: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS") received by the reporting person pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received shares of STERIS in an amount equal to the number of the reporting person's cancelled shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"). The reporting person's STERIS shares are subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS. F2 · ownership.nature: Richard C. Breeden is the managing member of Breeden Capital Partners LLC, managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC is in turn the general partner of Breeden Partners L.P. (the "Fund"). F3 · ownership.nature: Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 18:56 UTC | STERIS plc STE · Entity 3228 | GrantOrdinary Shares | 28,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021596 · doc4.xml · nonDerivative · entry 1 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,548 F1 · price: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS") received by the reporting person pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received shares of STERIS in an amount equal to the number of the reporting person's cancelled shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"). The reporting person's STERIS shares are subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerCareer Restricted Stock Units · Derivative | 12,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 12 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,716 shares Expires not disclosed F13 · derivative.exercise_price: These career restricted stock units were assumed by STERIS pursuant to the Scheme and converted to career restricted stock units of STERIS representing the right to receive 12,716 STERIS ordinary shares. These career restricted stock units are fully vested and will be settled in STERIS ordinary shares six months after the cessation of the reporting person's board service, subject to the terms and conditions of the award agreement. F13 · derivative.exercise_date: These career restricted stock units were assumed by STERIS pursuant to the Scheme and converted to career restricted stock units of STERIS representing the right to receive 12,716 STERIS ordinary shares. These career restricted stock units are fully vested and will be settled in STERIS ordinary shares six months after the cessation of the reporting person's board service, subject to the terms and conditions of the award agreement. F13 · derivative.expiration_date: These career restricted stock units were assumed by STERIS pursuant to the Scheme and converted to career restricted stock units of STERIS representing the right to receive 12,716 STERIS ordinary shares. These career restricted stock units are fully vested and will be settled in STERIS ordinary shares six months after the cessation of the reporting person's board service, subject to the terms and conditions of the award agreement. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 3,495 | Not disclosed Strike: $114.74 | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 11 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,495 shares Expires 2028-08-09 F12 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,495 ordinary shares of STERIS for $114.74 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F12 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,495 ordinary shares of STERIS for $114.74 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 4,058 | Not disclosed Strike: $86.23 | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 10 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,058 shares Expires 2027-08-09 F11 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,058 ordinary shares of STERIS for $86.23 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F11 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,058 ordinary shares of STERIS for $86.23 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 3,781 | Not disclosed Strike: $71.40 | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 9 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,781 shares Expires 2026-08-10 F10 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,781 ordinary shares of STERIS for $71.40 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F10 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,781 ordinary shares of STERIS for $71.40 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 4,110 | Not disclosed Strike: $64.05 | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 8 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,110 shares Expires 2025-08-31 F9 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,110 ordinary shares of STERIS for $64.05 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F9 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,110 ordinary shares of STERIS for $64.05 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 4,584 | Not disclosed Strike: $51.53 | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 7 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,584 shares Expires 2024-08-06 F8 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,584 ordinary shares of STERIS for $51.53 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F8 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,584 ordinary shares of STERIS for $51.53 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 4,657 | Not disclosed Strike: $43.92 | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 6 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,657 shares Expires 2023-08-08 F7 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,657 ordinary shares of STERIS for $43.92 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F7 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,657 ordinary shares of STERIS for $43.92 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 3,218 | Not disclosed Strike: $32.36 | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 5 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,218 shares Expires 2022-08-03 F6 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,218 ordinary shares of STERIS for $32.36 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F6 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,218 ordinary shares of STERIS for $32.36 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 3,121 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 4 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,121 shares Expires 2021-08-03 F5 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,121 ordinary shares of STERIS for $31.61 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F5 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,121 ordinary shares of STERIS for $31.61 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 3,133 | Not disclosed Strike: $32.34 | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · derivative · entry 3 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,133 shares Expires 2020-08-04 F4 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,133 ordinary shares of STERIS for $32.34 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F4 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,133 ordinary shares of STERIS for $32.34 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerOrdinary Shares, 10 pence par value | 72,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · nonDerivative · entry 2 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Below. Disclosed balance after: 0 F1 · price: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"), cancelled pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS"), in an amount equal to the number of the reporting person's cancelled Old STERIS shares. The reporting person's STERIS shares will be subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS. F2 · ownership.nature: Richard C. Breeden is the managing member of Breeden Capital Partners LLC, managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC is in turn the general partner of Breeden Partners L.P. (the "Fund"). F3 · ownership.nature: Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:37 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerOrdinary Shares, 10 pence par value | 28,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021554 · doc4.xml · nonDerivative · entry 1 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"), cancelled pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS"), in an amount equal to the number of the reporting person's cancelled Old STERIS shares. The reporting person's STERIS shares will be subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS. Read SEC document |
| February 20, 2019 Filed Feb 21, 2019 21:32 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 3,609 | $0.00 Strike: $28.08 | $0.00 |
DisclosureSEC source: 0001209191-19-012023 · doc4.xml · derivative · entry 3 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,609 shares Expires 2019-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 3,609 STERIS plc ordinary shares, which is fully vested, was received in conjunction with the "Combination" of STERIS Corporation and Synergy Health, Ltd. in exchange for an option to purchase 3,609 STERIS Corporation common shares for $28.08 per share, subject to the same terms and conditions as the original STERIS Corporation stock option. Read SEC document |
| February 20, 2019 Filed Feb 21, 2019 21:32 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionOrdinary Shares, 10 pence par value | 3,609 | $28.08 | $101,340.72 |
DisclosureSEC source: 0001209191-19-012023 · doc4.xml · nonDerivative · entry 1 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:18 UTC | STERIS plc STE · Entity 158792 | GrantCareer Restricted Stock Units · Derivative | 566 | $114.74 | $64,942.84 |
DisclosureSEC source: 0001209191-18-046219 · doc4.xml · derivative · entry 3 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,716 Underlying: Ordinary Shares · 566 shares Expires not disclosed F2 · derivative.exercise_price: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F4 · price: These Career Restricted Stock Units were issued to the Reporting Person in lieu of fees of $65,000. F3 · derivative.exercise_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. F3 · derivative.expiration_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:18 UTC | STERIS plc STE · Entity 158792 | GrantCareer Restricted Stock Units · Derivative | 872 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046219 · doc4.xml · derivative · entry 2 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,150 Underlying: Ordinary Shares · 872 shares Expires not disclosed F2 · derivative.exercise_price: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F3 · derivative.exercise_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. F3 · derivative.expiration_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:18 UTC | STERIS plc STE · Entity 158792 | GrantDirector Stock Option (right to buy) · Derivative | 3,495 | $0.00 Strike: $114.74 | $0.00 |
DisclosureSEC source: 0001209191-18-046219 · doc4.xml · derivative · entry 1 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,495 Underlying: Ordinary Shares · 3,495 shares Expires 2028-08-09 F1 · derivative.exercise_date: These nonqualified stock options are fully vested and are exercisable immediately. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:49 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 2,744 | Not disclosed Strike: $34.17 | Not disclosed |
DisclosureSEC source: 0001209191-18-009233 · doc4.xml · derivative · entry 3 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,744 shares Expires 2018-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: This option to purchase 2,744 STERIS plc ordinary shares, which is fully vested, was received in conjunction with the "Combination" of STERIS Corporation and Synergy Health, Ltd. in exchange for an option to purchase 2,744 STERIS Corporation common shares for $34.17 per share, subject to the same terms and conditions as the original STERIS Corporation stock option. F3 · derivative.exercise_date: This option to purchase 2,744 STERIS plc ordinary shares, which is fully vested, was received in conjunction with the "Combination" of STERIS Corporation and Synergy Health, Ltd. in exchange for an option to purchase 2,744 STERIS Corporation common shares for $34.17 per share, subject to the same terms and conditions as the original STERIS Corporation stock option. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:49 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionOrdinary Shares, 10 pence par value | 2,744 | $34.17 | $93,762.48 |
DisclosureSEC source: 0001209191-18-009233 · doc4.xml · nonDerivative · entry 1 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:23 UTC | STERIS plc STE · Entity 158792 | GrantCareer Restricted Stock Units · Derivative | 754 | $86.23 | $65,017.42 |
DisclosureSEC source: 0001209191-17-048595 · doc4.xml · derivative · entry 3 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,278 Underlying: Ordinary Shares · 754 shares Expires not disclosed F2 · derivative.exercise_price: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F4 · price: These Career Restricted Stock Units were issued to the Reporting Person in lieu of fees of $65,000. F3 · derivative.exercise_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. F3 · derivative.expiration_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:23 UTC | STERIS plc STE · Entity 158792 | GrantCareer Restricted Stock Units · Derivative | 1,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-048595 · doc4.xml · derivative · entry 2 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,524 Underlying: Ordinary Shares · 1,014 shares Expires not disclosed F2 · derivative.exercise_price: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F3 · derivative.exercise_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. F3 · derivative.expiration_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:23 UTC | STERIS plc STE · Entity 158792 | GrantDirector Stock Option (right to buy) · Derivative | 4,058 | $0.00 Strike: $86.23 | $0.00 |
DisclosureSEC source: 0001209191-17-048595 · doc4.xml · derivative · entry 1 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,058 Underlying: Ordinary Shares · 4,058 shares Expires 2027-08-09 F1 · derivative.exercise_date: These nonqualified stock options are fully vested and are exercisable immediately. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.